X4 Pharmaceuticals Inc (XFOR)
X4 Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, and commercializing therapies for rare immune system diseases. The company’s lead product is XOLREMDI, an oral small-molecule selective antagonist of the CXCR4 chemokine receptor, which is in phase 3 development for patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. X4 Pharmaceuticals also has licensing arrangements covering XOLREMDI and related CXCR4 programs in several geographies, including mainland China, Taiwan, Hong Kong and Macau through Abbisko Therapeutics, and Europe, Australia, and New Zealand through Norgine. In addition, Genzyme Corporation holds a license related to CXCR4 receptor programs for therapeutic, prophylactic, and diagnostic applications. The company is headquartered in Boston, Massachusetts, and its common stock trades on the NASDAQ under the ticker XFOR.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-XFOR
|
$3.25
|
5.7% Upside
|
Fair
|
$11.60
|
277.9% Upside
|
Bargain
|
Fair
|
0.0%
|
2.2x
|
17.9x
|
304.4 M
|
193.9 M
|
20.2%
|
-2.6
|
94.5%
|
